Vulval cancer incidence, mortality and survival in England: Age-related trends

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 121, Issue 6, 2014, Pages 728-738

  Lai, J ^a   Elleray, R ^a   Nordin, A ^a,b   Hirschowitz, L ^c,d   Rous, B ^e   Gildea, C ^a   Poole, J ^a,c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c Portland House   (United Kingdom)

^d BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e Eastern Office   (United Kingdom)

Author keywords

Age; incidence; mortality; survival; trends; vulval cancer

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PAGET SKIN DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREND STUDY; UNITED KINGDOM; VULVA CANCER; AGE DISTRIBUTION; CARCINOMA IN SITU; INCIDENCE; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; MIDDLE AGED; MORTALITY; PAPILLOMAVIRUS INFECTION; PATHOLOGY; POISSON DISTRIBUTION; REGISTER; RISK FACTOR; SENTINEL SURVEILLANCE; SQUAMOUS CELL CARCINOMA; SURVIVAL; TRENDS; VERY ELDERLY; VULVA TUMOR; VULVAL CANCER;

WART VIRUS VACCINE;

AGE; INCIDENCE; MORTALITY; SURVIVAL; TRENDS; VULVAL CANCER;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; ENGLAND; FEMALE; HUMANS; INCIDENCE; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; MIDDLE AGED; MORTALITY; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POISSON DISTRIBUTION; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SENTINEL SURVEILLANCE; SURVIVAL ANALYSIS; VULVAR NEOPLASMS;

EID: 85054107877     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12459     Document Type: Article

References (50)

1. World Health Organization (WHO). Human Papillomavirus and Related Cancers in United Kingdom, Summary Report 2010. Barcelona, Spain: WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre), 2010. [ www.who.int/hpvcentre ]. Accessed on 10 August 2012.
2. Sankaranarayanan R, Ferlay J,. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2006; 20: 207-25.
3. Parkin DM, Bray F,. The burden of HPV-related cancers. Vaccine 2006; 24: S11-25.
4. Office for National Statistics (ONS). Cancer Statistics Registrations, England (Series MB1) No. 41. ONS, 2010. [ http://www.ons.gov.uk/ons/dcp171778- 267154.pdf ]. Accessed 23 June 2012.
5. Janda M, Obermair A, Cella D, Crandon A, Trimmel M,. Vulvar cancer patients' quality of life: a qualitative assessment. Int J Gynecol Cancer 2004; 14: 875-81.
6. de Melo Ferreira AP, de Figueiredo EM, Lima RA, Cândido EB, de Castro Monteiro MV, de Figueiredo Franco TMR, et al. Quality of life in women with vulvar cancer submitted to surgical treatment: a comparative study. Eur J Obstet Gynecol Reprod Biol 2012; 165: 91-5.
7. Oonk MH, Van Os MA, de Bock GH, de Hullu JA, Ansink AC, van der Zee AG,. A comparison of quality of life between vulvar cancer patients after sentinel lymph node procedure only and inguinofemoral lymphadenectomy. Gynecol Oncol 2009; 113: 301-5.
8. Pilger A, Richter R, Fotopoulou C, Beteta C, Klapp C, Sehouli J,. Quality of life and sexuality of patients after treatment for gynaecological malignancies: results of a prospective study in 55 patients. Anticancer Res 2012; 32: 5045-9.
9. Mulvany NJ, Rayoo M, Allen DG,. Basal cell carcinoma of the vulva: a case series. Pathology 2012; 44: 528-33.
10. Robinson D, Coupland V, Møller H,. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in southeast England. Br J Cancer 2009; 100: 527-31.
11. Somoye GO, Mocroft A, Olaitan A,. Analysis of the incidence and mortality of vulval cancer in women in South East England 1960-1999. Arch Gynecol Obstet 2009; 279: 113-7.
12. Bodelon C, Madeleine MM, Voigt LF, Weiss NS,. Is the incidence of invasive vulvar cancer increasing in the United States? Cancer Causes Control 2009; 20: 1779-82.
13. Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D,. Epidemiology of vulvar and vaginal cancer in Germany. Arch Gynecol Obstet 2011; 284: 169-74.
14. Hampl M, Deckers-Figiel S, Hampl JA, Rein D, Bender HG,. New aspects of vulvar cancer: changes in localization and age of onset. Gynecol Oncol 2008; 109: 340-5.
15. Fay MP, Feuer EJ,. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med 1997; 16: 791-801.
16. Parkin D, Hakulinen T,. Analysis of survival. Cancer registration principles and methods. IARC Sci Publ 1991; 95: 159-76.
17. International Agency for Research on Cancer (IARC). Survival of Cancer Patients in Europe: The EUROCARE-2 Study. Lyon: International Agency for Research on Cancer, 1999.
18. Sant M, Aareleid T, Berrino F, Lasota MB, Carli P, Faivre J, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol 2003; 14: v61-118.
19. Coleman M, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011; 377: 127-38.
20. Statacorp. Stata Statistical Software, 12th edn. College Station, TX: Statacorp LP, 2011.
21. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V,. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006; 108: 1361-8.
22. Tavassoli FA, Devilee P,. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: World Health Organization; 2003.
23. Kurman R, Hedrick E, Ronnett B,. Blaustein's Pathology of the Female Genital Tract, 6th edn. London: Springer; 2011.
24. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA,. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006; 107: 1018-22.
25. Yap J, Baker L, Balega J, Chan K, Luesley D,. Impact of improving outcome guidance in gynaecological cancer on squamous cell carcinoma of the vulva in the West Midlands, UK. J Obstet Gynaecol 2011; 31: 754-8.
26. Department of Health. The NHS Cancer Plan, a Plan for Investment, a Plan for Reform. London: Department of Health; 2000.
27. Messing MJ, Gallup DG,. Carcinoma of the vulva in young women. Obstet Gynecol 1995; 86: 51-4.
28. Kumar S, Shah JP, Bryant CS, Imudia AN, Morris RT, Malone JM Jr,. A comparison of younger vs older women with vulvar cancer in the United States. Am J Obstet Gynecol 2009; 200: e52-5.
29. Canavan TP, Cohen D,. Vulvar cancer. Am Fam Physician 2002; 66: 1269-74.
30. Scurry J, Flowers L, Wistuba I, Vanin K, Mulvany N, Reyes H, et al. Human papillomavirus, lichen sclerosis and vulvar squamous cell carcinoma. Int J Gynecol Cancer 1998; 8: 298-306.
31. Madsen BS, Jensen HL, van den Brule AJ, Wohlfahrt J, Frisch M,. Risk factors for invasive squamous cell carcinoma of the vulva and vagina-population-based case-control study in Denmark. Int J Cancer 2008; 122: 2827-34.
32. Goffin F, Mayrand MH, Gauthier P, Alobaid A, Lussier C, Provencher D, et al. High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. J Med Virol 2006; 78: 814-9.
33. Al-Ghamdi A, Freedman D, Miller D, Poh C, Rosin M, Zhang L, et al. Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. Gynecol Oncol 2002; 84: 94-101.
34. Gargano JW, Wilkinson EJ, Unger ER, Steinau M, Watson M, Huang Y, et al. Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction. J Low Genit Tract Dis 2012; 16: 471-9.
35. Chaturvedi AK,. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010; 46: S20-6.
36. Kenter GG, Welters MJ, Valentijn ARP, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 1838-47.
37. Joura EA, Lösch A, Haider-Angeler M-G, Breitenecker G, Leodolter S,. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 2000; 45: 613-5.
38. Iversen T, Tretli S,. Intraepithelial and invasive squamous cell neoplasia of the vulva: trends in incidence, recurrence, and survival rate in Norway. Obstet Gynecol 1998; 91: 969-72.
39. Trent Cancer Registry. Profile of Cervical Cancer in England: Incidence, Mortality and Survival. Sheffield, UK: Trent Cancer Registry, 2011.
40. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-301.
41. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
42. Nygård M, Aagnes B, Bray F, Møller B, Mork J,. Population-based evidence of increased survival in human papillomavirus-related head and neck cancer. Eur J Cancer 2012; 48: 1341-6.
43. Monk BJ, Burger RA, Lin F, Parham G, Vasilev SA, Wilczynski SP,. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol 1995; 85: 709-15.
44. Stroup A, Harlan L, Trimble E,. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the US. Gynecol Oncol 2008; 108: 577-83.
45. Grann A, Frøslev T, Olesen A, Schmidt H, Lash T,. The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987-2009: a registry-based cohort study. Br J Cancer 2013; 109: 265-71.
46. Land LH, Dalton SO, Jensen M-B, Ewertz M,. Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008. Breast Cancer Res Treat 2012; 131: 1013-20.
47. Newschaffer CJ, Penberthy L, Desch CE, Retchin SM, Whittemore M,. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 1996; 156: 85.
48. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW,. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. J Am Med Assoc 2001; 285: 885-92.
49. Koppert L, Lemmens V, Coebergh J, Steyerberg E, Wijnhoven B, Tilanus H, et al. Impact of age and co-morbidity on surgical resection rate and survival in patients with oesophageal and gastric cancer. Br J Surg 2012; 99: 1693-700.
50. National Cancer Intelligence Network (NCIN) Routes to Diagnosis Workbook. National Cancer Intelligence Network; 2012 [ http://www.ncin.org.uk/ publications/routes-to-diagnosis ]. Accessed 12 April 2013.